AWG Member News
-
Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis
The post Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis appeared first on Melinta.... Read more
-
CORMEDIX INC. TO REPORT FOURTH QUARTER AND FISCAL YEAR 2022 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON MARCH 30, 2023
Berkeley Heights, NJ – March 21, 2023 – CorMedix Inc. (Nasdaq: CRMD),... The post CORMEDIX INC. TO REPORT FOURTH QUARTER AND FISCAL YEAR 2022 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON MARCH 30, 2023 appeared first on CorMedix | Prevention of cardiac, renal and infectious diseases.... Read more
-
Paratek Pharmaceuticals Announces Full-Year 2022 Revenue of $160.3 Million
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $98.7 Million from the Core Commercial Business, a 45% Increase Over the Prior Year -- Continued Progress on the Rare Disease Nontuberculous Mycobacteria (NTM) & BARDA Project BioShield Anthrax Programs BOSTON, March ...... Read more
-
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
... Read more
-
Iterum Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
... Read more
-
Iterum Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023
... Read more
-
Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 16
BOSTON, March 08, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Thursday, March 16, 2023 at 8:30 a.m. EST to provide a corporate update and report its financial results for fourth quarter and full... Read more
-
Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 16
BOSTON, March 08, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Thursday, March 16, 2023 at 8:30 a.m. EST to provide a corporate update and report its financial results for fourth quarter and full... Read more
-
Venatorx Pharmaceuticals Appoints Tomas J. Heyman as Non-Executive Chairman
Dr. Michael Diem Steps Down from Board of Directors Malvern, PA, March 7, 2023 – Venatorx Pharmaceuticals, a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with difficult-to-treat drug resistant gram-negative bacterial infections and viral infections, today announced changes to its Board of Directors. Tomas J. Heyman... Read more
-
Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update
... Read more
-
CORMEDIX INC. ANNOUNCES REGULATORY AND MANUFACTURING UPDATES
Berkeley Heights, NJ – March 2, 2022 – CorMedix Inc. (Nasdaq: CRMD),... The post CORMEDIX INC. ANNOUNCES REGULATORY AND MANUFACTURING UPDATES appeared first on CorMedix | Prevention of cardiac, renal and infectious diseases.... Read more
-
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on February 28, 2023,...... Read more
-
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on February 28, 2023,...... Read more
-
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on February 28, 2023,...... Read more
-
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on January 31, 2023, the...... Read more
-
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on January 31, 2023, the...... Read more
-
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on January 31, 2023, the...... Read more
-
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on January 31, 2023, the...... Read more
-
Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
The post Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis appeared first on Melinta.... Read more
-
CORMEDIX INC. ANNOUNCES PROMOTIONS IN COMMERCIAL AND TECH OPS
Berkeley Heights, NJ – January 17, 2023 – CorMedix Inc. (Nasdaq:... The post CORMEDIX INC. ANNOUNCES PROMOTIONS IN COMMERCIAL AND TECH OPS appeared first on CorMedix | Prevention of cardiac, renal and infectious diseases.... Read more
-
Paratek Pharmaceuticals Announces Inclusion of NUZYRA® (omadacycline) in China's National Reimbursement Drug List (NRDL)
National Healthcare Security Administration Adds NUZYRA to NRDL for Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure InfectionsBOSTON, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that China's National Healthcare Security...... Read more
-
Paratek Pharmaceuticals Announces Inclusion of NUZYRA® (omadacycline) in China's National Reimbursement Drug List (NRDL)
National Healthcare Security Administration Adds NUZYRA to NRDL for Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure InfectionsBOSTON, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that China's National Healthcare Security...... Read more
-
Paratek Pharmaceuticals Announces Inclusion of NUZYRA® (omadacycline) in China's National Reimbursement Drug List (NRDL)
National Healthcare Security Administration Adds NUZYRA to NRDL for Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure InfectionsBOSTON, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that China's National Healthcare Security...... Read more
-
Paratek Pharmaceuticals Announces Inclusion of NUZYRA® (omadacycline) in China's National Reimbursement Drug List (NRDL)
National Healthcare Security Administration Adds NUZYRA to NRDL for Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure InfectionsBOSTON, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that China's National Healthcare Security...... Read more
-
Paratek Pharmaceuticals Announces Inclusion of NUZYRA® (omadacycline) in China's National Reimbursement Drug List (NRDL)
National Healthcare Security Administration Adds NUZYRA to NRDL for Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure InfectionsBOSTON, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that China's National Healthcare Security...... Read more
-
The Antimicrobials Working Group Announces Appointment of Christine Ann Miller as Board Chair
The post The Antimicrobials Working Group Announces Appointment of Christine Ann Miller as Board Chair appeared first on Melinta.... Read more
-
Acurx Pharmaceuticals to Present at the Emerging Growth Conference on January 25, 2023
... Read more
-
Iterum Therapeutics Reports Employment Inducement Grant
... Read more
-
Nabriva Therapeutics Provides Corporate Update
-Company To Focus on Preserving Cash to Fund Orderly Wind Down of Operations-... Read more
-
Paratek Pharmaceuticals Receives $36.4 Million Milestone Payment Associated with the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield Contract
Total Procurement-related Revenue Recognition of $38.1 Million to Paratek in December 2022Procurement Triggered by Positive Top-Line Data from Pilot Efficacy Study of NUZYRA for the Treatment of Pulmonary Anthrax Announced in...... Read more